Welcome to our dedicated page for NMTR news (Ticker: NMTR), a resource for investors and traders seeking the latest updates and insights on NMTR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NMTR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NMTR's position in the market.
9 Meters Biopharma announced a public offering of 46,153,847 shares at $0.65 per share, targeting gross proceeds of approximately $30 million. The offering includes a 30-day option for underwriters to purchase up to 6,923,077 additional shares. Proceeds will fund the development of NM-002 for Short Bowel Syndrome and larazotide for celiac disease, along with general corporate purposes. The offering is set to close on December 15, 2020, pending customary conditions.
9 Meters Biopharma (NASDAQ:NMTR) has announced the initiation of a proposed underwritten public offering of its common stock. The offering includes a potential 30-day option for underwriters to purchase an additional 15% of the shares. The net proceeds will be utilized for the clinical development of NM-002 for short bowel syndrome and larazotide for celiac disease, along with general corporate purposes. This offering is subject to market conditions.
9 Meters Biopharma (NASDAQ:NMTR) receives orphan drug designation from the FDA for NM-003, a long-acting GLP-2 receptor agonist, aimed at preventing acute graft versus host disease (aGvHD). This designation, granted on December 9, 2020, qualifies the company for development incentives like tax credits for clinical testing. NM-003 utilizes proprietary XTEN technology to enhance circulating half-life and aims to improve treatment options for aGvHD, a serious condition affecting transplant recipients.
9 Meters Biopharma (NASDAQ: NMTR) announced promising topline results from its Phase 1b/2a trial for NM-002, a long-acting GLP-1 receptor agonist targeting short bowel syndrome (SBS). All 9 participants showed rapid clinical improvements in total stool output (TSO), with significant declines within 48 hours post-injection. The trial confirmed a strong safety profile, with most treatment-emergent adverse events being mild. The company plans to consult with the FDA in Q1 2021 to discuss the next steps for NM-002, potentially enhancing the quality of life for SBS patients.
9 Meters Biopharma (NASDAQ: NMTR) reported promising preliminary results from a study on NM-102, a next-generation microbiome modulator, which showed efficacy in an aggressive melanoma model. The research demonstrated that NM-102, alone or in combination with immune checkpoint inhibitors (ICIs), improved survival rates compared to ICIs alone. The company plans to pursue an IND-enabling pathway for NM-102, aimed at advancing its development. This study represents a significant step in understanding the role of gut microbiome in immunomodulation.
9 Meters Biopharma (NASDAQ: NMTR) will participate in two virtual conferences in November 2020. The H.C. Wainwright Annual Israel Conference is scheduled for November 12, featuring presentations from top management, including CEO John Temperato. The A.G.P. Virtual Healthcare Symposium will follow on November 19, also with one-on-one meetings with company executives. These events are pivotal for discussing ongoing projects, including NM-002 for Short Bowel Syndrome and larazotide for celiac disease. Interested stakeholders can access the webcasts on the company’s website.
9 Meters Biopharma (NASDAQ:NMTR) announced its participation in two upcoming investor conferences in September 2020. The first is the H.C. Wainwright: 22nd Annual Global Investment Conference, scheduled for September 15, where CEO John Temperato will present at 10:00 am ET. The second is the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, also featuring Temperato at the same time. Investors can join via webcast. For more details, visit the company’s website.
9 Meters Biopharma (NASDAQ:NMTR) announced the formation of a new Scientific Advisory Board (SAB) featuring six experts in gastroenterology to enhance clinical development efforts. The SAB will assist in progressing the company's co-lead assets: NM-002 for Short Bowel Syndrome and larazotide for celiac disease. CEO John Temperato emphasized the significant expertise the board brings, particularly for their upcoming Phase 3 trial in celiac disease. This move is anticipated to bolster the company’s strategy in addressing unmet medical needs.
9 Meters Biopharma (NASDAQ: NMTR) announced participation in the "Prepping ahead of Data" Conference Call Series on August 18, 2020. The call will feature discussions on preliminary Phase 1/2 data for short bowel syndrome expected in the second half of 2020. Key executives, including President & CEO John Temperato, will present insights. The company focuses on treatments for rare gastroenterological diseases, advancing NM-002 and larazotide through clinical trials. For further details, visit 9meters.com.
9 Meters Biopharma (NASDAQ:NMTR) will participate in the Prepping ahead of Data Conference Call Series on August 18, 2020, to discuss preliminary Phase 1/2 data expected in the second half of 2020 for its drug targeting Short Bowel Syndrome. The call will feature key executives, including John Temperato, President & CEO. Interested parties can register for the call here. A replay will be available until August 25, 2020.
The company is focused on gastroenterology and is advancing NM-002 and larazotide in its development pipeline.
FAQ
What is the market cap of NMTR (NMTR)?
